Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

por Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael
Publicado 2019

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglyca...

por Hövelmann, Ulrike, Raiter, Yaron, Chullikana, Anoop, Liu, Mark, Donnelly, Charles, Lawrence, Tracey, Sengupta, Nilanjan, CL, Gopu, Ranganna, Gopinath, Barve, Abhijit
Publicado 2021

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog(®)) in Patients with Type 1 Diabetes After 24 Weeks:...

por Blevins, Thomas C., Raiter, Yaron, Sun, Bin, Donnelly, Charles, Shapiro, Roxann, Chullikana, Anoop, Rao, Anita, Vashishta, Laxmikant, Ranganna, Gopinath, Barve, Abhijit
Publicado 2022

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 s...

por Sun, Bin, Sengupta, Nilanjan, Rao, Anita, Donnelly, Charles, Waichale, Vinit, Roy, Arnab Sinha, Ramaswamy, Shilpa, Pathak, Divya, Bowsher, Ronald R., Raiter, Yaron, Aubonnet, Patrick, Barve, Abhijit
Publicado 2021